ブルキンサ、未治療CLL患者において画期的な6年無増悪生存率74%を達成
This data highlights BRUKINSA's sustained efficacy and durability in a challenging patient population.
BRUKINSA demonstrated 74% 6-year PFS in treatment-naïve CLL patients.
百济神州公布了一项III期研究的里程碑数据，显示BRUKINSA在初治慢性淋巴细胞白血病（CLL）患者中实现了六年74%的无进展生存率（PFS）。这一重要的长期疗效数据巩固了BRUKINSA作为CLL领先治疗选择的地位。
This data highlights BRUKINSA's sustained efficacy and durability in a challenging patient population. For APAC, where CLL is a significant concern, these results reinforce the value of BRUKINSA as a long-term treatment option, potentially improving patient outcomes and quality of life across the region.
BRUKINSA is a key product for BeiGene in APAC. Demonstrating such strong long-term efficacy in treatment-naïve CLL patients is highly relevant for oncologists and patients in the region, supporting its continued adoption and clinical use.
Where this signal fits in the broader landscape.
BeiGene、2025年第4四半期および通期決算を発表
BeOne Medicines、2025年第4四半期および通期決算を発表
ビーゲン社のPD-1阻害薬ティスレリズマブ、日本で承認取得 グローバル製薬大手に挑む
BeOne Medicines、2025年第4四半期および通期決算を発表へ
BeiGene社、ソノロトクラックスが再発・難治性マントル細胞リンパ腫（R/R MCL）で世界初の承認を取得
https://www.beigene.com/press-releases/brukinsa-delivers-landmark-74-percent-6-year-progression-free-survival-in-patients-with-treatment-naive-chronic-lymphocytic-leukemia
Read Full SourceGet curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
Sign in to save notes on signals.
ログイン